|
Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime
Time?
Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation? Apr 16, 2026 Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603 Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time? Apr 16, 2026 Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium Apr 16, 2026 Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 |
Tisagenlecleucel (tisa-cel) in pediatric and young adult patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) and minimal residual disease (MRD) at the end of frontline consolidation (EOC). Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10000-10000, June 2026. <br/> 2026-06-01T07:00:00Z SPARTO: A phase I study of PD-1 inhibitor spartalizumab (PDR001) in combination with low dose of pazopanib in pediatric relapsed/refractory tumors. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10001-10001, June 2026. <br/> 2026-06-01T07:00:00Z Targeting metastatic sites with radiation and outcomes in high-risk pediatric rhabdomyosarcoma. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10002-10002, June 2026. <br/> 2026-06-01T07:00:00Z Digital health intervention for comorbid insomnia and neurocognitive impairment in adult survivors of childhood cancer: Results from a randomized clinical trial. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10003-10003, June 2026. <br/> 2026-06-01T07:00:00Z The ASPIRES study: Promoting colorectal cancer surveillance in childhood cancer survivors—A randomized intervention trial from the Childhood Cancer Survivor study (CCSS). Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10004-10004, June 2026. <br/> 2026-06-01T07:00:00Z Prediction of anthracycline-related cardiomyopathy in long-term childhood cancer survivors: The power of survivor-specific polygenic risk score—A COG-ALTE03N1 study. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10005-10005, June 2026. <br/> 2026-06-01T07:00:00Z Primary breast malignancies in adolescents and young adults: The MD Anderson Cancer Center experience. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10006-10006, June 2026. <br/> 2026-06-01T07:00:00Z Characteristics and survival of 4N and non-4N metastatic neuroblastoma across treatment eras: A report from the International Neuroblastoma Risk Group Task Force. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10007-10007, June 2026. <br/> 2026-06-01T07:00:00Z Real-world experience of a pediatric precision oncology protocol utilizing paired somatic and germline sequencing at a single institution: Interim analysis. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10008-10008, June 2026. <br/> 2026-06-01T07:00:00Z Harnessing OMOP-CDM for multisite collaborations to measure cardiovascular risk factors and cardiovascular disease in the early survivorship period for children, adolescents, and young adults. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10009-10009, June 2026. <br/> 2026-06-01T07:00:00Z Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo). Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 1001-1001, June 2026. <br/> 2026-06-01T07:00:00Z Association of neighborhood-level vulnerability with health behavior patterns in survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE). Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10010-10010, June 2026. <br/> 2026-06-01T07:00:00Z Thematic game intervention as a novel psychosocial support to reduce sedation needs and anxiety in pediatric neuro-oncology patients during radiotherapy: A prospective cohort study (2020–2025). Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10011-10011, June 2026. <br/> 2026-06-01T07:00:00Z Alrizomadlin (APG-115) alone or in combination with lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs). Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10012-10012, June 2026. <br/> 2026-06-01T07:00:00Z RAPID: A pilot feasibility study of rapid dinutuximab infusion in patients with relapsed/refractory (RR) high-risk neuroblastoma (HRNBL). Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10013-10013, June 2026. <br/> 2026-06-01T07:00:00Z Interim analysis of CaboMain: A prospective, single-arm phase 2 clinical trial of cabozantinib as maintenance therapy for patients with “ultra-high-risk” pediatric solid tumors. Journal of Clinical Oncology, Volume 44, Issue 16_suppl, Page 10014-10014, June 2026. <br/> 2026-06-01T07:00:00Z |
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. 2026-05-31
Perioperative Apalutamide in High-Risk Localized Prostate Cancer In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. 2026-05-31
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. 2026-05-31
A Watershed Moment in the Perioperative Treatment of Prostate Cancer Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either... 2026-05-31
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. 2026-05-30
Precision Intensification in Metastatic Prostate Cancer The treatment of advanced prostate cancer has undergone significant improvements, with two developments proven to be especially transformative. The first advance was the establishment of treatment intensification in patients with metastatic castration-sensitive prostate cancer (hereafter referred to as metastatic androgen pathway modulation–sensitive [APMS] disease, in accordance with the recently updated... 2026-05-30
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. 2026-05-29
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. 2026-05-29
Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules The treatment landscape of multiple myeloma has undergone a profound transformation over the past two decades, driven by deeper insights into disease biology, refined patient stratification, the integration of new prognostic biomarkers, and sustained therapeutic innovation. Today, most patients receive proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies as frontline... 2026-05-29
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. 2026-05-28
Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia Ugandan children with sickle cell anemia who received 10 years of hydroxyurea therapy had sustained laboratory and clinical benefits, improved growth, and few toxic effects. 2026-05-28
Resolution of PML after Treatment with Virus-Specific T Cells and HCT Two patients with inborn errors of immunity and progressive multifocal leukoencephalopathy received polyomavirus-specific T cells, followed by allogeneic hematopoietic transplantation with good neurologic outcomes. 2026-05-28
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. 2026-05-18
Case 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemia A 50-year-old woman was admitted to the hospital because of vaginal bleeding and anemia. She had a history of fibroids and 1 month of progressive thrombocytopenia. A diagnosis was made. 2026-05-14
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease In this study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression. 2026-05-07
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer In a phase 1–2 study of daraxonrasib, treatment-related adverse events of grade 3 or higher occurred in 30% of patients with previously treated RAS-mutated pancreatic cancer, and up to 35% of patients had an objective response. 2026-05-07
Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B The administration recently announced a new payment model to align some Medicare Part B drug payments with international pricing benchmarks. Various factors could affect the model’s scope and impact. 2026-05-07
Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer The authors describe the scientific foundations of a phase 1–2 study of daraxonrasib to treat metastatic pancreatic ductal adenocarcinomas. 2026-05-07
Reducing Bacterial Contamination of Blood Bags with a Double Knot In a study involving 180 blood bags, use of a double-knot closure rather than the usual single knot prevented bacterial contamination. This strategy may reduce the risk of blood-product contamination in resource-limited settings. 2026-05-07
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors Among patients with hemophilia A, the annualized rate of treated bleeding events with Mim8 was more than 96% lower than with on-demand therapy and more than 42% lower than with clotting factor prophylaxis. 2026-04-30
|
|
|
| |||
|
[Editorial] War in the Middle East: collateral damage
A month after the USA and Israel launched attacks on Iran, Iran and the USA agreed to a conditional 2-week ceasefire on April 8, 2026. However, strikes continued in Lebanon, and after peace talks failed to come to a resolution an end to the war is no closer at the time of writing and the situation in the region remains precarious. Furthermore, the effects of the US–Israel–Iran war are being felt not only in the region, but also globally, and the impact on health care worldwide is under-appreciated and likely long-lasting. Fri, 01 May 2026 00:00:00 -0700
[Comment] AKT-targeted triplet therapy in advanced breast cancer The advent of CDK4/6 inhibitors combined with endocrine therapy has substantially transformed the treatment approach for patients with HR+/HER2– metastatic breast cancer;1 however, acquired resistance inevitably develops, making the optimal sequencing of subsequent targeted therapies a substantial challenge. Aberrant activation of the PI3K/AKT/PTEN signalling axis is frequently identified as a key contributor to CDK4/6 inhibitor cross-resistance, providing a robust biological rationale for therapeutic intervention. Fri, 01 May 2026 00:00:00 -0700
[Comment] Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy. The meta-analysis of Beshr and colleagues1 in The Lancet Oncology provides the most up-to-date analysis of data from phase 3 trials comparing CDK4/6 inhibitors plus endocrine therapy with endocrine therapy alone. By consolidating survival results, efficacy of this drug class in treatment of HR+/HER2– metastatic breast cancer is reaffirmed. Fri, 01 May 2026 00:00:00 -0700
[Comment] An old tool for new strategies in advanced prostate cancer Prostate-specific antigen (PSA) was discovered in 1960 and introduced as a biomarker for prostate cancer in 1987.1 Since then, PSA has been used for screening, detecting recurrence after prostatectomy or radiotherapy, and monitoring treatment response. Early work also demonstrated that PSA concentrations measured 6–9 months after initiating castration represent a major prognostic factor in metastatic castration-sensitive prostate cancer.2 Fri, 01 May 2026 00:00:00 -0700
[Comment] Refined outcome prediction in patients with extremity soft tissue sarcoma The rarity and heterogenous presentation of extremity soft tissue sarcomas complicates large-scale studies on diagnosis, disease monitoring, and outcome prediction. Histological subtype, grading, tumour size, location, resectability (with wide margins), administration of adjuvant or neoadjuvant radiotherapy, and chemotherapy all influence oncological outcomes, including local recurrence and risk of distant metastasis, as well as overall survival (figure).1 Given that the estimated prognosis of patients with soft tissue sarcoma guides decisions on individual treatment concepts, patient counselling, and follow-up strategies,2 the accurate prediction of oncological outcomes is important. Fri, 01 May 2026 00:00:00 -0700
[Comment] Ionising radiation and cancer: a UN review of the recent epidemiological evidence In 2019, the UN Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), whose mandate is to undertake scientific evaluations of the sources, effects, and risk of ionising radiation,1–3 convened a group of experts to review the latest epidemiological evidence on radiation and cancer risk. The updated report focuses on low-level radiation exposures; it has recently been approved and will be published in 2026.4 Fri, 01 May 2026 00:00:00 -0700
[Comment] Academic clinical cancer trials to improve patient outcomes Cancer clinical trials are conducted by both the commercial and non-commercial sectors. Whereas clinical trials conducted by the commercial sector aim for the marketing authorisation of new drugs, the primary characteristic of independent clinical trials conducted by the academic sector is the capacity to address a wide range of clinical research questions that are generally not addressed by the drug development industry. Crucial examples include the optimisation of surgical and radiation treatments, drug dose and treatment duration, multimodality combinations, sequence of treatments, head-to-head comparison of therapeutic strategies, better identification of patients who will or will not benefit, and addressing the needs of underserved patient populations. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma We congratulate Hermann Einsele and colleagues on their phase 3 CARTITUDE-4 trial, a landmark study poised to reshape the therapeutic landscape of relapsed myeloma. By finding a significant overall survival advantage with ciltacabtagene autoleucel (cilta-cel) compared with pomalidomide–bortezomib–dexamethasone or daratumumab–pomalidomide–dexamethasone in patients with lenalidomide-refractory myeloma with one to three previous lines of therapy, CARTITUDE-4 provides compelling evidence that earlier use of CAR T-cell therapy can alter disease trajectory. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma – Authors' reply We thank Jowon Laura Kim and S Vincent Rajkumar for their comments. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data We read with interest the systematic review by C Tang and colleagues1 and compliment the authors for their comprehensive primary analysis of six randomised clinical trials (RCTs) comparing metastasis-directed therapy (MDT) with standard of care (SOC) in oligometastatic prostate cancer. However, we identified several important design concerns and methodological limitations that could compromise the validity and interpretation of the findings. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data – Authors' reply We thank André Vis and Kim de Vries for their interest in our WOLVERINE study.1 We agree that, optimally, there will be well conducted phase III trials to inform the benefit of metastasis-directed therapy (MDT) for oligometastatic prostate cancer. However, these trials have yet to be reported, and in the interim, clinicians are left with an increasingly common clinical scenario that requires evidence-based direction. The highest-level data available are randomised phase 2 trials. However, heterogeneity exists between these trials given inherent differences and the timeframes over which they were run. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: e218–30 Alger E, Regnault, A, Dueck AC, et al. A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR). Lancet Oncol 2026; 27: e218–30—The appendix of this Policy View has been corrected as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 461–69 Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol 2026; 27: 461–69—In this Article, the title has been corrected to “[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study”. This correction has been made to the online version as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[News] Carcinogenicity of tris(chloropropyl) phosphate, butyraldehyde, and cumyl hydroperoxide In March, 2026, a Working Group of 12 scientists from nine countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of tris(chloropropyl) phosphate (TCPP), butyraldehyde, and cumyl hydroperoxide. Fri, 27 Mar 2026 08:00:04 +0000
[News] US oil blockade pushes Cuba's health system into crisis A US oil blockade causing several power blackouts in Cuba has led to tens of thousands of delayed surgeries while the health system tries to prioritise urgent care, including radiotherapy for 16 000 patients with cancer and chemotherapy for another 12 400 patients with cancer, say Cuban health authorities and the UN. Fri, 27 Mar 2026 23:30:01 +0000
[News] US cancer vaccines research at “tipping point” as NCI backs $200 million initiative The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have launched a partnership to raise nearly US$200 million to fund clinical trials for cancer vaccines, including mRNA-based approaches for patients at high risk of tumour recurrence. Fri, 27 Mar 2026 23:30:01 +0000
[News] Senators demand explanation for US Preventive Services Task Force halt 19 US senators wrote to Health and Human Services Secretary Robert F Kennedy Jr on March 24, 2026, demanding he explain why the US Preventive Services Task Force (USPSTF)—the independent expert panel that has determined which cancer screenings and other preventive care Americans can access at no cost for four decades—has not met for a year. They called on Kennedy to submit an overdue, legally required annual USPSTF report to Congress, and to fill five vacancies among the 16 Task Force seats. Thu, 02 Apr 2026 22:30:01 +0000
[News] Canada's Yukon Territory publishes First Nations Cancer Strategy Canada's vast Yukon Territory in the country's northwest has published its first ever First Nations Cancer Strategy, aiming to improve cancer diagnosis, treatment, and care across the board for its First Nations people, who make up just less than 20% of the territory's population of around 48 000 people (2025 estimate). Some three-quarters of the population live in Whitehorse, the territory's capital near the southern border with the Province of British Colombia. Thu, 02 Apr 2026 22:30:03 +0000
[News] European Breast Cancer Conference 2026 Preliminary results of the ADARNAT pilot phase suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in patients with limited node disease. Amparo Garcia-Tejedor (Hospital Universitari de Bellvitge, Gynecology, Hospitalet de Llobregat, Spain) presented results from the pilot phase of ADARNAT trial, an open-label, randomised, phase 3 multicentre trial across 23 Spanish hospitals. 272 patients with breast cancer (cT1–T4b, and cN0–cN1) treated with neoadjuvant therapy and 1–2 positive sentinel lymph nodes at surgery were randomly assigned to receive ART or ALND. Thu, 02 Apr 2026 22:30:01 +0000
[News] UK MHRA–NICE pathway to create faster regulatory approval A new aligned pathway has been established by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) to facilitate earlier patient access to medicines, according to recently published guidance. Fri, 10 Apr 2026 22:30:01 +0000
[News] Trump's 2027 budget calls for further cuts to health research Medical groups are preparing to lobby Congress over health cuts proposed in the 2027 budget by the US Trump administration in the hope that lawmakers will ensure funding when spending plans are negotiated in the coming months. Thu, 16 Apr 2026 22:30:01 +0000
[Perspectives] CHEMO MAN—or how we used to remember It caught my attention one Sunday as I did inpatient rounds. Pinned to a corkboard, fading slightly at the edges, the drawing looked almost childish at first glance. A smiling stick figure labelled CHEMO MAN, organs sketched in block letters and arrows pointing outwards with names of drugs and toxicities carefully written in pen. Doxorubicin for the heart. Bleomycin for the lungs. Cisplatin for the kidneys. Methotrexate for the liver. Vincristine for the nerves. A mnemonic rendered as a body and, unintentionally, a theory of learning. Fri, 01 May 2026 00:00:00 -0700
[Perspectives] Turning breast cancer into art with Cancer Research UK On Jan 20–25, 2026, the Business Design Centre in London, UK, hosted the annual London Art Fair, which for the first time had Cancer Research UK (London, UK) as its official charity partner. Cancer Research UK, used their platform at the London Art Fair to showcase two artists whose lives have been affected by breast cancer. Tucked away in a quiet upstairs corner of the fair, slightly aside from the bustling central area, Cancer Research UK's relatively small exhibition displayed the works of Dr Helen Anahita Wilson and Carole Ellis, two revolutionary and incredibly talented artists and survivors of breast cancer. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers These findings highlight the substantial and growing burden of cancers, especially in low-income and middle-income countries, where many people who develop cancer die undiagnosed. Accounting for demographic and epidemiological trends as well as health system factors, our modelling framework enables evaluation of targeted interventions to strengthen the cancer workforce and improve diagnostic pathways across diverse geographical and socioeconomic settings. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers Disparities in global cancer survival are large and are expected to persist on current trends without transformative policy action. Our modelling framework provides comprehensive, country-level projections of survival and mortality for multiple cancers, accounting for demographic and epidemiological trends, as well as health system barriers and workforce constraints. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types Investments to strengthen the cancer workforce will be essential to reduce global cancer mortality and improve timely diagnosis and survival. Strategic scale-up of personnel, particularly in diagnostics, alongside innovative strategies such as digital health solutions and role delegation, could result in substantial improvements in cancer outcomes. Policy makers should prioritise data-driven workforce planning as a crucial component of comprehensive cancer control strategies. Fri, 01 May 2026 00:00:00 -0700
[Articles] Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial The combination of fulvestrant, ipatasertib, and palbociclib showed preliminary signs of clinical activity and showed expected adverse events in heavily pretreated patients with HR+/HER2– metastatic breast cancer, warranting further evaluation in those with CDK4/6 inhibitor-refractory disease. Fri, 01 May 2026 00:00:00 -0700
[Articles] CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-negative advanced breast cancer. Benefits in progression-free survival and overall survival were consistent across major clinical subgroups. Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed. Fri, 01 May 2026 00:00:00 -0700
[Articles] Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit. Fri, 01 May 2026 00:00:00 -0700
[Articles] Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC. Thu, 09 Apr 2026 22:30:01 +0000
[Articles] On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials Metastatic volume or nodal status influence survival rates associated with on-treatment serum PSA categories, including for undetectable PSA. Radiological features and serum PSA could be combined to better predict survival. PSA at 24 weeks showed strongest associations with overall survival, although a PSA concentration of 0·2 ng/mL or less at any timepoint predicted favourable outcome. These findings could inform prognosis and warrant evaluation for treatment selection in clinical trials. Fri, 01 May 2026 00:00:00 -0700
[Articles] Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study BayeSarc is a continuously updatable, accurate, and precise prognostic tool for soft tissue sarcomas in the extremities. It reduces uncertainty, adapts to temporal changes, and refines variable weights. Its incorporation into the Sarculator app enables immediate clinical use, with potential to improve patient counselling, guide treatment decisions, and refine trial design. More broadly, the BSL framework provides an innovative and generalisable approach to prognostication in rare cancers, moving beyond the traditional two-step development–validation paradigm, enabling more efficient use of patient data. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium Oligometastatic cancer is characterised by a low volume of metastases to a small number of anatomical sites. However, evaluating the impact of metastases-directed therapies (MDTs) on overall survival or quality of life is often challenging. Current clinical trials use a wide range of primary endpoints that might not be validated or suited to MDT. To address this issue, we did a systematic review of international trial registries, alongside a Delphi consensus process involving 30 experts and five patient representatives. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment This multisociety, multidisciplinary consensus—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—was developed to standardise the assessment of ablation margins in liver tumour thermal ablation. A modified Delphi process, consisting of two online surveys and a hybrid (online and in-person meeting in Innsbruk) consensus meeting of 72 experts from North America, South America, Europe, and Asia. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards Thermal ablation offers a safer, less invasive, and more cost-effective curative-intent treatment for selected patients with primary and metastatic liver tumours than surgery; when done with appropriate technique, ablation can deliver similar oncological outcomes. However, effectiveness in routine practice varies because structured training, planning, and procedural governance remain scarce. These international multidisciplinary, multi-society guidelines—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—define key domains contributing to procedural difficulty and practice variation in liver tumour thermal ablation. Fri, 01 May 2026 00:00:00 -0700
|
First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial
Envafolimab combined with Rh‐endostatin demonstrated favorable efficacy and tolerable toxicity in patients with PD‐L1–positive, advanced driver‐gene negative NSCLC. Fri, 29 May 2026 23:21:15 -0700 Top advances of the year: Gastroesophageal cancer Fri, 29 May 2026 22:26:21 -0700 Amivantamab in advanced non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real‐world data from the Italian ATLAS Registry Fri, 29 May 2026 22:24:11 -0700 Top advances of the year: Radiopharmaceutical therapy for prostate cancer Fri, 29 May 2026 22:20:13 -0700 A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors Fri, 29 May 2026 22:15:27 -0700 Impact of patient‐reported taxane‐induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG‐ACRIN EAZ171 TIPN was common and strongly predicted taxane dose reduction in Black patients. The FACT‐GOG/NTx 4‐item subscale performed best, supporting its use in future trials. Although early TIPN did not predict long‐term functional decline, persistent neuropathy adversely affected HRQOL, underscoring the importance of early identification and supportive care to improve dose delivery and equity in breast cancer outcomes. Fri, 29 May 2026 22:14:47 -0700 Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and survival in people with incident cancer in UK Biobank Wed, 27 May 2026 17:01:08 -0700 Blood‐based cell‐free DNA and multitarget stool RNA screening tests to detect colorectal cancer: A systematic review Wed, 27 May 2026 04:07:35 -0700 Genetic ancestry–concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration‐resistant prostate cancer This study identified genetic ancestry–concordant ceramide metabolites that were associated with outcomes in patients with mCRPC who received treatment with ARPI from the Abi Race and PANTHER studies (ClinicalTrials.gov identifiers NCT01940276 and NCT03098836, respectively). Tue, 26 May 2026 00:01:15 -0700 Correction to “Health care discrimination and self‐reported health in transgender, gender nonconforming, and nonbinary individuals with cancer” Fri, 22 May 2026 23:40:35 -0700 Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact Cy‐JAK/STAT pathway mutations are uncommon in AML, but each mutation has distinct biologic and clinical characteristics. The worse survival observed in patients with JAK2‐mutated AML largely appeared to be driven by the co‐occurrence of high‐risk characteristics. Blast‐phase MPN was associated with a dismal prognosis. Fri, 22 May 2026 23:06:00 -0700 Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis Low testosterone at diagnosis does not appear to predict a reduced mortality risk when adding docetaxel to RT and ADT in otherwise healthy patients with nonmetastatic high‐risk PC, whereas normal testosterone does, which provides evidence to support testosterone group as a predictive biomarker. Fri, 22 May 2026 22:12:52 -0700 Bridging the gap to improve skin cancer prevention practices in childhood cancer survivors Wed, 20 May 2026 22:50:16 -0700 Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma Wed, 20 May 2026 04:00:11 -0700 Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial These findings support the feasibility of incorporating venetoclax into a fludarabine and melphalan conditioning regimen in older adults with AML/MDS. Notably, the low rates of GVHD and relapse associated with this venetoclax‐based conditioning regimen support further study of this platform [ClinicalTrials.gov Identifier: NCT05084027]. Wed, 20 May 2026 03:48:23 -0700 Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM‐3 Wed, 20 May 2026 03:25:25 -0700 Issue Information Wed, 20 May 2026 03:01:15 -0700 Understudied and overlooked: Addressing sexual quality of life for couples facing metastatic breast cancer Wed, 20 May 2026 00:00:00 -0700 |
Genomic Therapy Matching in Rare and Refractory Cancers
This cohort study assesses whether a tiered, evidence-based framework for matching genomic biomarkers to therapies is associated with differential overall survival in patients with advanced solid tumors. Diagnostic Performance of Anti–Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma This multicenter, prospective cohort study assesses the diagnostic performance of anti–Epstein-Barr virus (EBV) BNLF2b in outpatients presenting with suspected nasopharyngeal carcinoma, and compares it with the anti-EBV capsid antigen, anti-EBV early antigen, and anti-EBV nuclear antigen 1 assays. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial This randomized clinical trial evaluates the efficacy and safety of bireociclib plus fulvestrant in hormone receptor–positive, Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer This cohort study validates a novel parsimonious, interpretable, and generalizable model for predicting incident pancreatic ductal adenocarcinoma. Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer This cohort study compares real-world overall survival between sequential and concurrent radiotherapy and immunotherapy among patients with newly diagnosed advanced non–small cell lung cancer. Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial This secondary analysis of a randomized clinical trial explores treatment outcome preferences among older adults with advanced cancer, specifically whether survival or quality of life matters most to the patient. Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis. Survival Without Adjuvant Therapy for Low-Risk Endometrial Cancer With Isolated Tumor Cells This cohort study assesses overall survival without adjuvant therapy in patients with uterine factor–based low-risk endometrial cancer who had isolated tumor cells present in regional lymph nodes. Extensive Oral Ulcerations After Stem Cell Transplant A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis? Implementing Cancer Medicines on the WHO Model Lists of Essential Medicines Into National Systems This Viewpoint discusses national systems implementation of cancer medicines included in the WHO Model Lists of Essential Medicines. Obesity Control’s Underestimated Potential for Cancer Prevention This Viewpoint discusses obesity prevention and control as an underestimated and underutilized strategy in the prevention of numerous cancers. Insurance Barriers to Next-Generation Sequencing Testing in Lung Cancer—When Policy Delays Care This Viewpoint discusses insurance barriers to next-generation sequencing (NGS) testing for patients with non–small cell lung cancer and proposes policy solutions to address these barriers. The Next Frontier for Transparency in Cancer Randomized Clinical Trials—Data and Safety Monitoring Boards This Viewpoint discusses increasing the transparency in cancer randomized clinical trials through the use of data and safety monitoring boards. JAMA Oncology—TheYear in Review, 2025 Performance of Stereotactic Radiotherapy vs Hippocampal-Avoidance Whole Brain Radiation Delivering Precision Oncology at Scale—Infrastructure, Evidence, and the Path Forward Person-Centered Care in Geriatric Oncology—Understanding What Matters Most Local Consolidative Therapy in Lung Cancer This The Good Cancer, the Barely Cancer, and the Incurable Cancer This essay discusses the author’s reflection on his third cancer diagnosis and how he has lived with cancer throughout his life. The Vocabulary of Survival Possible Biases May Have Limited Study on Ultraprocessed Food Intake Possible Biases May Have Limited Study on Ultraprocessed Food Intake—Reply Error in Tables 2 and 3 JAMA Oncology JAMA Oncology Peer Reviewers in 2025 |
|
|
| |||
|
[Editorial] Mental health at the heart of haematology
May is a time to elevate mental health awareness. In the USA, May is designated as Mental Health Awareness Month; Europe marks Mental Health Week (May 4–8); and the UK observes Mental Health Awareness Week (May 11–17). These events invite a renewed collective focus on connection, resilience, and hope for the more than one billion people worldwide who live with mental health conditions, placing a substantial burden on individuals and health systems. Yet, our understanding of mental health within the fields of haematology and haematological oncology remains limited. Fri, 01 May 2026 00:00:00 -0700
[Comment] Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma Since the year 2000, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have authorised many novel cancer therapies based on phase 1–2 single-arm trials.1,2 Most of these were granted as conditional marketing authorisations (EMA) or Accelerated Approvals (FDA), which aim to provide early access to promising therapies in diseases with high unmet medical need. Acknowledging that single-arm trials can show biological activity but cannot reliably establish whether an experimental treatment is better than the current standard, these approvals are contingent on demonstration of clinical benefit in subsequent confirmatory randomised trials. Fri, 01 May 2026 00:00:00 -0700
[In Focus] Leveraging TikToks in clinical practice TikToks (short vertical videos) are increasingly infiltrating our lives, as well as those of our patients. In mid-2020, TikTok was one of the fastest growing social media platforms, with over half a billion active users and with TikToks also routinely viewed on other social media platforms or shared directly by friends and family. Armed with this knowledge, in my role as Director of the donor recruitment organisation Stem Cell Club, I led the development of a library of TikToks to engage young adults to stem-cell donation. Fri, 01 May 2026 00:00:00 -0700
[In Focus] From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials Clinical trials in multiple myeloma continue to fail populations most affected by the disease, with Black individuals remaining profoundly underrepresented in the studies that define contemporary treatment standards. Multiple myeloma is the second most common haematological malignancy, and the incidence, prevalence, and disability-adjusted life years attributable to the disease have increased over time, with mortality rates remaining high. Despite this burden, the therapeutic landscape of multiple myeloma has been transformed by the development of novel agents evaluated in clinical trials, resulting in substantial improvements in survival and meaningful gains in quality of life. Fri, 01 May 2026 00:00:00 -0700
[Articles] Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial Very early PET-guided intensification with BrECADD yields high activity in advanced-stage classic Hodgkin lymphoma while sparing most patients intensive chemotherapy. Fri, 01 May 2026 00:00:00 -0700
[Articles] Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial Pirtobrutinib was highly active and well tolerated, regardless of previous exposure to covalent BTK inhibitors, and might be a promising new therapeutic option for patients with relapsed or refractory Waldenström macroglobulinaemia, particularly in those previously exposed to covalent BTK inhibitors, for whom durable and effective treatments are needed. Fri, 01 May 2026 00:00:00 -0700
[Articles] Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis Since the year 2000, early-phase trials in relapsed or refractory diffuse large B-cell lymphoma have shown more than a doubling of response rates, driven primarily by cellular and bispecific antibody therapies, while maintaining low treatment-related mortality. These results provide risk-benefit trends in early-phase trials and define contemporary benchmarks for clinicians, investigators and regulators. Fri, 01 May 2026 00:00:00 -0700
[Articles] Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial In this setting, Peg-IFN combined with nilotinib induced higher initial rates of MR4·5 compared to TKI monotherapy, despite additional side effects. The onset of psychiatric events might promote immediate cease of Peg-IFN and psychiatrist advice Whether this early molecular response translates into sustained treatment-free survival should be studied in a randomised trial sufficiently powered for this outcome. Fri, 01 May 2026 00:00:00 -0700
[Review] Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies The development of novel T-cell redirecting immune therapies—including immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor T cells, and virus-specific T cells—represents a major advancement in the treatment of haematological malignancies. Although such therapies have strong evidence for efficacy in the treatment of B-cell neoplasms, several unique challenges are encountered when using these therapies for the treatment of T-cell malignancies. In this Review, we discuss the application of T-cell modulating immune therapies in T-cell neoplasms, with a focus on the complicated bidirectional interactions between malignant and bystander T cells in disease pathogenesis, and the resultant challenges affecting the design and deliverability of T-cell modulating therapies in this cohort. Fri, 03 Apr 2026 22:30:00 +0000
[Review] Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network Autosomal dominant acute porphyrias are rare inherited disorders of haem biosynthesis characterised by accumulation of potentially neurotoxic porphyrin precursors and attacks of severe abdominal pain with autonomic and neuropsychiatric features. Disease severity ranges from asymptomatic individuals to those with recurrent, life-threatening attacks. The International Porphyria Network invited 34 acute porphyria specialists from 17 countries to form an expert panel. The invited group included clinicians from diverse specialities (ie, internal medicine, haematology, endocrinology, gastroenterology, hepatology, neurology, and biochemistry), together with laboratory scientists and patient representatives. Fri, 01 May 2026 00:00:00 -0700
[Clinical Picture] An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass A 69-year-old woman was referred to our department after monoclonal gammopathy was detected during routine testing. Her medical history included dyslipidaemia, hypothyroidism, and right hip replacement due to congenital dysplasia. Physical examination, complete blood count, and serum biochemical tests were unremarkable. Immunofixation revealed monoclonal IgGλ (total IgG 1060 mg/dL), with a normal free light chain (FLC) ratio. Urine immunofixation was negative. A bone marrow biopsy showed 12% clonal plasma cell infiltration, consistent with smouldering multiple myeloma (SMM) pending whole-body, low-dose CT (WBLD–CT). Thu, 02 Apr 2026 22:30:01 +0000
[Clinical Picture] Protein-losing enteropathy in marginal zone lymphoma: tissue is the issue A 67-year-old woman was diagnosed with nodal marginal zone lymphoma with IgMκ paraproteinaemia, circulating monoclonal B cells, multifocal lymph node involvement (MYD88WT), and splenomegaly. Rituximab monotherapy yielded partial metabolic remission on PET–CT and an IgM concentration decrease from 15·4 g/L to 12·4 g/L (normal range: 0·4–2·3 g/L). However, the patient reported severe progressive diarrhoea (up to 50 times per day). A 13 kg weight loss resulted in total parenteral nutrition dependence. Fri, 01 May 2026 00:00:00 -0700
|
Unlocking the locking secret behind FNAlT
Volume 147, Issue 22 May 28 2026 CD117-targeted HCT preconditioning in AML and MDS Volume 147, Issue 22 May 28 2026 A reassessment of anti–CAR T-cell expansion strategies Volume 147, Issue 22 May 28 2026 CSNK1E as a key to unlocking drug persistence in DLBCL Volume 147, Issue 22 May 28 2026 Cracking the CODEX of the leukemic BM microenvironment Volume 147, Issue 22 May 28 2026 GATA have it: another pathway regulated by GATA1 Volume 147, Issue 22 May 28 2026 Novel functions of WPB proteins seem to cluster with VWF Volume 147, Issue 22 May 28 2026 Structural basis of HPA-1a alloimmunization in FNAIT and allosteric regulation of integrin conformation Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is caused by transplacental passage of maternal antiplatelet antibodies and severely affects approximately 1 in 1000 births. Zhang and colleagues probed the structure-function relationships underpinning interactions of alloantibodies against the most common target, human platelet antigen 1a (HPA-1a). Their data in this Plenary Paper help explain why some alloantibodies cause severe hemorrhagic FNAIT while others result in milder, asymptomatic thrombocytopenia.
Volume 147, Issue 22 May 28 2026 Thrombotic thrombocytopenic purpura: celebrating 25 years of ADAMTS13 No disease better exemplifies how the science of hematology transforms care and outcomes for a disease than thrombotic thrombocytopenic purpura (TTP). Scully, Carter, and Subhan review how a feared syndrome of idiopathic, acute multiorgan failure in the presence of microangiopathic hemolytic anemia came to be recognized as a deficiency of ADAMTS13 25 years ago, paving the way for high-resolution understanding of pathogenesis and multiple targeted treatment modalities enabling precision therapy. They also identify ongoing questions guiding current trials for both acquired and congenital TTP.
Volume 147, Issue 22 May 28 2026 How I treat HLH-like toxicities after immune effector cell therapy Hemophagocytic lymphohistiocytosis (HLH)–like manifestations after chimeric antigen receptor T-cell therapy, now referred to as immune effector cell–associated HLH-like syndrome and high-grade cytokine release syndrome (CRS) with HLH-like multiorgan dysfunction, are increasingly recognized, and their management is evolving. Johnson and colleagues use 2 illustrative cases to outline their practical approach to these major clinical challenges. They emphasize early identification, use of anticytokine therapy with either emapalumab or ruxolitinib when organ toxicities worsen despite conventional CRS-directed treatment, and the need for ancillary supportive care as central to success.
Volume 147, Issue 22 May 28 2026 Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS While graft-versus-leukemia activity is the major therapeutic advantage of allogeneic hematopoietic stem cell transplantation (HCT), clearance of leukemia pre-HCT improves outcomes and may improve engraftment. The humanized anti-CD117 antibody briquilimab disrupts critical stem cell factor–CD117 signaling to normal and leukemic stem cells. Muffly et al report a phase 1 trial studying the addition of briquilimab prior to nonmyeloablative conditioning in patients with acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), demonstrating major reductions in leukemic stem cells, minimal toxicity, and encouraging but preliminary posttransplant outcomes. Such precision conditioning approaches warrant further clinical investigation.
Volume 147, Issue 22 May 28 2026 Antigen-boosted CD4CAR T cells fail to expand or control viremia in multiple nonhuman primate models of HIV Volume 147, Issue 22 May 28 2026 CSNK1E sustains stemlike drug persistence in diffuse large B-cell lymphoma Neither current mutational nor transcriptional profiling of bulk lymphoma biopsies explains why some cases of diffuse large B-cell lymphoma (DLBCL) are resistant to standard therapy. To discover the molecular identity of chemotherapy-tolerant persister cell populations, Li et al longitudinally profiled DLBCL samples from patients who prove to have refractory or relapsing disease. These are less differentiated cells, akin to memory B cells, and their enhanced stemness is dependent on upregulated casein kinase 1ε (CSNK1E). These and other emerging data provide new avenues for elimination of relapse-initiating residual lymphoma.
Volume 147, Issue 22 May 28 2026 High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression Although this is not apparent by standard microscopy, the bone marrow has functionally distinct areas where external signals govern stem cell behavior. It is postulated that these are disrupted in leukemias. Li and colleagues used high-resolution imaging and a murine model of BCR::ABL1+ blast-phase chronic myeloid leukemia (CML) to map the extent of leukemia-induced changes in the bone marrow microenvironment. They show leukemia-induced remodeling creating immune-privileged niches through T-cell exhaustion, as well as vascular abnormalities that fail to support normal hematopoeisis, refining our knowledge of how leukemia overwhelms normal marrow function.
Volume 147, Issue 22 May 28 2026 The GATA1 N terminus coordinates metabolic reprogramming in erythropoiesis The zinc finger transcription factor GATA1 is a master regulator of erythropoiesis, coordinating the differentiation program. In some conditions such as Diamond-Blackfan anemia and associated with some mutations in Down syndrome, a short form of GATA1 is dominant. Ling and colleagues define the function of this isoform, demonstrating in primary erythroid cells how it can reprogram metabolism through its regulation of PKM, the gene encoding pyruvate kinase M1/2.
Volume 147, Issue 22 May 28 2026 Clusterin maintains hemostatic equilibrium by stabilizing VWF multimers in plasma Volume 147, Issue 22 May 28 2026 Morphologic and flow cytometric features of menin inhibitor–induced pseudoprogression in KMT2A-rearranged acute myeloid leukemia Volume 147, Issue 22 May 28 2026 Rust BJ, Kean LS, Colonna L, Brandenstein KE, Poole NH, Obenza W, Enstrom MR, Maldini CR, Ellis GI, Fennessey CM, Huang M-L, Keele BF, Jerome KR, Riley JL, Kiem H-P, Peterson CW. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. Blood. 2020;136(15):1722-1734. Volume 147, Issue 22 May 28 2026 |
Correction to “DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond‐Blackfan Anemia Syndrome”
Sun, 24 May 2026 20:30:30 -0700 Response to: “Refining Combined‐Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma” Sat, 23 May 2026 05:46:12 -0700 Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T‐Cell Lymphoma: A Prospective, Multicenter, Observational Study Thu, 21 May 2026 01:11:38 -0700 Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis Tue, 19 May 2026 22:00:11 -0700 Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic Tue, 19 May 2026 21:20:13 -0700 Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta‐Analysis of CAR T‐Cell Therapy for Hematologic Malignancies Tue, 19 May 2026 18:17:58 -0700 CAR T‐Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study Sun, 17 May 2026 18:38:28 -0700 Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ALL Sun, 17 May 2026 18:35:09 -0700 Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management Fri, 15 May 2026 05:16:46 -0700 Chronic Anemia Patients Demonstrate Diffuse Demyelination Thu, 14 May 2026 20:46:50 -0700 Performance Evaluation of a Novel Non‐Invasive Monitoring Device for At‐Home Neutropenia Detection in a Multicenter Cancer Cohort Thu, 14 May 2026 06:04:44 -0700 Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma Thu, 14 May 2026 04:45:26 -0700 Accuracy of Diagnosis in Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis (MPN‐SVT) Thu, 14 May 2026 01:34:28 -0700 Pre‐Transplant MRD Negativity and Age Under 40 Predict Superior Long‐Term Survival in Relapsed/Refractory B‐ALL After CAR‐T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6‐Year Follow‐Up Wed, 13 May 2026 22:22:43 -0700 Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant Wed, 13 May 2026 18:21:00 -0700 RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma Tue, 12 May 2026 22:35:13 -0700 Thrombotic Microangiopathy, Cryoglobulinemia, and Acute Kidney Injury in Patients With Monoclonal Gammopathy: A Case Series Tue, 12 May 2026 22:25:15 -0700 The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation Tue, 12 May 2026 05:33:33 -0700 Striking Bone Marrow Plasmacytosis Resulting From Visceral Leishmaniasis Tue, 12 May 2026 05:22:04 -0700 Management of Iron Overload in Infants and Toddlers With Diamond–Blackfan Anemia Syndrome: A French–Italian Study Mon, 11 May 2026 00:04:14 -0700 Real‐World Efficacy and Safety of Glofitamab‐Based Salvage Therapy in Chinese Patients With Relapsed or Refractory Aggressive B‐Cell Lymphomas Sun, 10 May 2026 23:46:12 -0700 |
|
|
| |||
|
Popping FVIII concentrates into an updated classification May 26 2026 - Volume 10, Issue 10 On the RAdR in relapsed T-cell lymphoma May 26 2026 - Volume 10, Issue 10 CD19 CAR T cells for B-ALL with EMD May 26 2026 - Volume 10, Issue 10 Platelets pull: how thrombin drives contractility May 26 2026 - Volume 10, Issue 10 Six-year FIX-padua gene therapy in hemophilia B May 26 2026 - Volume 10, Issue 10 Yes, we can omit TBI for ALL! May 26 2026 - Volume 10, Issue 10 Progress over perfection: evolving treatments in LCH May 26 2026 - Volume 10, Issue 10 Chewing the fat: the role of total cholesterol in MPN management May 26 2026 - Volume 10, Issue 10 Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective May 26 2026 - Volume 10, Issue 10 Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners May 26 2026 - Volume 10, Issue 10 Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia May 26 2026 - Volume 10, Issue 10 Selinexor plus ruxolitinib in JAK inhibitor–naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study May 26 2026 - Volume 10, Issue 10 A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma May 26 2026 - Volume 10, Issue 10 Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia May 26 2026 - Volume 10, Issue 10 Low flow cytometry events in detecting CNS involvement in pediatric B-cell precursor ALL: NGS validation and prognostic significance May 26 2026 - Volume 10, Issue 10 Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B May 26 2026 - Volume 10, Issue 10 Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis May 26 2026 - Volume 10, Issue 10 Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study May 26 2026 - Volume 10, Issue 10 Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study May 26 2026 - Volume 10, Issue 10 Burnout in sickle cell disease–focused hematology-oncology–trained physicians: a national cross-sectional study May 26 2026 - Volume 10, Issue 10 Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study May 26 2026 - Volume 10, Issue 10 Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS May 26 2026 - Volume 10, Issue 10 CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review May 26 2026 - Volume 10, Issue 10 Digenic and multigenic heterozygous FHL genotypes are common but clinically silent in the general population May 26 2026 - Volume 10, Issue 10 Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma May 26 2026 - Volume 10, Issue 10 Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL May 26 2026 - Volume 10, Issue 10 Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma May 26 2026 - Volume 10, Issue 10 Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study May 26 2026 - Volume 10, Issue 10 Proteogenomic features define subtypes of mantle cell lymphoma May 26 2026 - Volume 10, Issue 10 Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines May 26 2026 - Volume 10, Issue 10 Validation of ICC hierarchical classification in secondary AML May 26 2026 - Volume 10, Issue 10 IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation May 26 2026 - Volume 10, Issue 10 Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients May 26 2026 - Volume 10, Issue 10 Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms May 26 2026 - Volume 10, Issue 10 Regulation of platelet contractility by agonists present across a thrombus May 26 2026 - Volume 10, Issue 10 Plasma proteome signatures are predictive of mortality in sickle cell disease May 26 2026 - Volume 10, Issue 10 Multiomics analysis of red blood cells reveals thalassemia severity beyond globin gene mutations May 26 2026 - Volume 10, Issue 10 A revised classification of FVIII concentrates: rationale and novel metrics May 26 2026 - Volume 10, Issue 10 Rat models of thrombotic thrombocytopenic purpura reveal crucial role of placental ADAMTS13 in perinatal survival May 26 2026 - Volume 10, Issue 10 Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders May 26 2026 - Volume 10, Issue 10 Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation May 26 2026 - Volume 10, Issue 10 BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease May 26 2026 - Volume 10, Issue 10 Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome May 26 2026 - Volume 10, Issue 10 Structure of factor VII Gla domain bound to EPCR May 26 2026 - Volume 10, Issue 10 Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes May 26 2026 - Volume 10, Issue 10 Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma May 26 2026 - Volume 10, Issue 10 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Decompression with or without Duraplasty for Chiari I and Syringomyelia
New England Journal of Medicine, Volume 394, Issue 20, Page 2015-2025, May 28, 2026.
Stem-Cell–Derived Biologic Ventricular Assist Tissue in Heart Failure New England Journal of Medicine, Volume 394, Issue 20, Page 1991-2001, May 28, 2026.
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer New England Journal of Medicine, Volume 394, Issue 20, Page 2002-2014, May 28, 2026.
Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism New England Journal of Medicine, Volume 394, Issue 20, Page 1979-1990, May 28, 2026.
Hematopoietic Stem-Cell Gene Therapy for Cystinosis New England Journal of Medicine, Volume 394, Issue 20, Page 2064-2066, May 28, 2026.
Transcatheter or Surgical Aortic-Valve Replacement at 7 Years New England Journal of Medicine, Volume 394, Issue 20, Page 2066-2070, May 28, 2026.
Resolution of PML after Treatment with Virus-Specific T Cells and HCT New England Journal of Medicine, Volume 394, Issue 20, Page 2061-2064, May 28, 2026.
Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia New England Journal of Medicine, Volume 394, Issue 20, Page 2059-2061, May 28, 2026.
Patching Up Damaged Hearts New England Journal of Medicine, Volume 394, Issue 20, Page 2054-2055, May 28, 2026.
Retraction: Bronchial Casts from Inhalation of Forest-Fire Smoke. N Engl J Med 2026;394:1634. New England Journal of Medicine, Volume 394, Issue 20, Page 2064-2064, May 28, 2026.
Colles’ Fracture New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.
Cutting to the Chase New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.
Money and Misdiagnosis New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.
Cardiovascular Risk Factors — Lifestyle Modifications New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.
Getting Serious about Tickborne Diseases — Shifting Research Priorities New England Journal of Medicine, Volume 394, Issue 20, Page 1971-1973, May 28, 2026.
A Eulogy for Structural Competence? New England Journal of Medicine, Volume 394, Issue 20, Page 1974-1976, May 28, 2026.
Prehospital Whole Blood in Traumatic Hemorrhage — a Randomized Controlled Trial New England Journal of Medicine, Ahead of Print.
Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease New England Journal of Medicine, Ahead of Print.
Intravascular Ultrasound–Guided or Angiography-Guided Complex High-Risk PCI New England Journal of Medicine, Ahead of Print.
Angiography-Derived Fractional Flow Reserve to Guide PCI New England Journal of Medicine, Ahead of Print.
Angiography-Based Physiology to Guide Coronary Revascularization New England Journal of Medicine, Ahead of Print.
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus New England Journal of Medicine, Ahead of Print.
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation New England Journal of Medicine, Ahead of Print.
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage New England Journal of Medicine, Ahead of Print.
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy New England Journal of Medicine, Ahead of Print.
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia New England Journal of Medicine, Ahead of Print.
Human Infection with Highly Pathogenic Avian Influenza A(H5N5) Virus New England Journal of Medicine, Ahead of Print.
NEJM Outbreaks Update — Andes Hantavirus New England Journal of Medicine, Ahead of Print.
Seeing the Left Main Coronary Artery Clearly — Is IVUS Always Necessary? New England Journal of Medicine, Ahead of Print.
Redefining Physiology in the Cardiac Catheterization Laboratory New England Journal of Medicine, Ahead of Print.
A Major Step toward a Cure for Hepatitis B Infection New England Journal of Medicine, Ahead of Print.
Childhood Vaccine Hesitancy New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions
Volume 31, Issue 6, June 2026, oyag165 Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors Volume 31, Issue 6, June 2026, oyag133 Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma Volume 31, Issue 6, June 2026, oyag159 Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis Volume 31, Issue 6, June 2026, oyag148 Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis Volume 31, Issue 6, June 2026, oyag172 Resilience in symptom response to cancer treatment: a new lens for examining variable symptom trajectories in older adults with advanced cancer Volume 31, Issue 6, June 2026, oyag094 Knowledge and awareness of colorectal cancer in central Uganda: a community cross-sectional survey Volume 31, Issue 6, June 2026, oyag181 Female sex is associated with worse survival in laryngeal head and neck squamous cell carcinoma Volume 31, Issue 6, June 2026, oyag167 Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program Volume 31, Issue 6, June 2026, oyag169 Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia Volume 31, Issue 6, June 2026, oyag099 The albumin–bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy Volume 31, Issue 6, June 2026, oyag179 Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors Volume 31, Issue 6, June 2026, oyag131 Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis Volume 31, Issue 6, June 2026, oyag137 Selective internal radiotherapy and chemosaturation show equivalent survival in metastatic uveal melanoma: a retrospective multicenter study Volume 31, Issue 6, June 2026, oyag152 Temozolomide reconsidered: Real-World evidence in resistant melanoma cases Volume 31, Issue 6, June 2026, oyag184 Outcomes of immunotherapy in medulloblastoma: a systematic review Volume 31, Issue 6, June 2026, oyag109 Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products Volume 31, Issue 6, June 2026, oyag154 Adherence to oral antineoplastic agents, an overview and meta-analysis Volume 31, Issue 6, June 2026, oyag168 Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC Volume 31, Issue 6, June 2026, oyag151 Exploring biologically-based complementary and alternative medicine use among Irish cancer survivors: findings from a national survey Volume 31, Issue 6, June 2026, oyag127 Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer Volume 31, Issue 6, June 2026, oyag142 Tumor growth rate as an intermediate trial endpoint Volume 31, Issue 6, June 2026, oyag149 |
Digital Therapeutics for Fecal Incontinence: What Real-World Data Can Support, and What It Cannot Diseases of the Colon & Rectum.69(6):1663-1665, June 2026. Reinterpreting Outcomes Following Different Neoadjuvant Treatment Approaches for Locally Advanced Rectal Cancer: Perspectives of the Discerning Reader Diseases of the Colon & Rectum.69(6):1666-1670, June 2026. Rupert B. Turnbull Jr, M.D., and Norma N. Gill: Founders of Enterostomal Therapy Diseases of the Colon & Rectum.69(6):1671-1678, June 2026. Rethinking Intestinal Stem Cells: Why Fgfbp1+ Progenitors Might Be More Critical Than the Lgr5+ Population Diseases of the Colon & Rectum.69(6):1679-1681, June 2026. Ulcerative Colitis-Associated Neoplasia Diseases of the Colon & Rectum.69(6):1682-1686, June 2026. Expert Commentary on Ulcerative Colitis–Associated Neoplasia Diseases of the Colon & Rectum.69(6):1687, June 2026. Textbook Outcome After IPAA for Ulcerative Colitis: A Nationwide Multicenter Study and Its Implications for Long-term Quality of Life Diseases of the Colon & Rectum.69(6):1688-1696, June 2026. Short-term Surgical Outcomes After Transanal Restorative Proctocolectomy With IPAA: A Comparison of Close Rectal Dissection and Modified Total Mesorectal Excision Diseases of the Colon & Rectum.69(6):1697-1701, June 2026. Tumor Necrosis Factor Alpha Inhibitors Reduce Staged Surgery Rate and Prevent Postoperative Endoscopic Recurrence in Patients With Crohn’s Disease Diseases of the Colon & Rectum.69(6):1702-1711, June 2026. A Digital Therapeutic Pelvic Health System Improves Fecal Incontinence Symptoms in a Real-World Patient Cohort Diseases of the Colon & Rectum.69(6):1712-1721, June 2026. Clinician and Patient Stakeholders Prioritize Rectal Prolapse Research Themes Through an International Delphi Process Diseases of the Colon & Rectum.69(6):1722-1731, June 2026. “Nobody Told Me”: A Qualitative Study of Sexual and Reproductive Concerns After Treatment for Early-Onset Colorectal Cancer Diseases of the Colon & Rectum.69(6):1732-1740, June 2026. Urinary Function After Laparoscopic Surgery in Very Low Rectal Cancer Diseases of the Colon & Rectum.69(6):1741-1748, June 2026. Influence of Circular Stapler Size and Number of Linear Stapler Firings on Anastomotic Leakage in Colorectal Surgery: A Retrospective Analysis of 1491 Patients Diseases of the Colon & Rectum.69(6):1749-1755, June 2026. Financial Toxicity Following Locally Advanced Rectal Cancer Treatment Diseases of the Colon & Rectum.69(6):1756-1765, June 2026. A Critical Appraisal of Colorectal Surgery Fellowship Standardized Letters of Recommendations Using Objective Criteria Diseases of the Colon & Rectum.69(6):1766-1771, June 2026. Selected Abstracts Diseases of the Colon & Rectum.69(6):1772-1776, June 2026. Robotic Splenic Flexure Colectomy With End-To-End Handsewn Anastomosis Diseases of the Colon & Rectum.69(6):1777, June 2026. Robotic-Assisted Reversal of Hartmann’s Procedure With Retroileal Tunnel of the Transverse Colon Diseases of the Colon & Rectum.69(6):1778, June 2026. Robotic Extended Left Colectomy With Colorectal Anastomosis Via Retroileal Window Diseases of the Colon & Rectum.69(6):1779-1780, June 2026. |
||
|
| |||
|
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years,1 it varies widely for some cancers among AYAs who are diagnosed with cancer. For example, AYAs have substantially worse ... Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States Investigators used data from the Surveillance, Epidemiology, and End Results (SEER) database to analyze trends in multiple myeloma mortality in the United States from 1975 to 2023. Their findings were published in Oncotarget. Tuesday, May 5, 2026 10:38 AM Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer On May 22, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate targeting trophoblast cell surface antigen 2 (TROP2), for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for ... Friday, May 22, 2026 11:39 AM Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma In two complementary preclinical studies published in Blood, investigators reported that mezigdomide, a cereblon E3 ligase modulator, may help overcome T-cell dysfunction in multiple myeloma, thereby enhancing the activity of BCMA-directed CAR T-cell and bispecific T-cell engager therapies. These... Friday, May 22, 2026 10:44 AM AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar, according to findings presented during the Congress of the... Wednesday, May 20, 2026 12:45 PM Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results from a two-arm pilot randomized trial that will be presented by Marchetti at the 2026 ASCO Annual... Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors A 4-week structured yoga intervention improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial that will be presented at the 2026 ASCO Annual Meeting (Abstract 12004). The analysis also suggested that... Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer Patients with advanced prostate cancer treated with darolutamide experienced significantly less objectively assessed cognitive decline over 24 weeks than those receiving enzalutamide, according to results from the prospective, randomized open-label phase II ARACOG (AFT-47) trial to be presented at... GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers Real-world data suggest that GLP-1 receptor agonists (RAs) may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findings to be presented at the 2026 ASCO Annual Meeting (Abstract 3143). GLP-1 receptor expression ... Early-Stage Breast Cancer: Losing Weight, Gaining Quality of Life A telephone-based weight loss intervention improved physical function and other patient-reported outcomes among women with early-stage breast cancer and overweight or obesity, according to findings from the health outcomes (HO)-1 substudy of the phase III Breast Cancer WEight Loss (BWEL) trial,... Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity Researchers have developed a novel diagnostics tool to detect gene fusions in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with greater sensitivity than standard detection algorithms, according to findings from a study published in The Journal of Molecular Diagnostics. Wednesday, May 20, 2026 12:45 PM Study Shows Potential Missing Patient Information in SEER Database A significant number of patients with cancer—particularly those with more advanced disease who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information in the Surveillance, Epidemiology, and End Results (SEER)... Wednesday, May 20, 2026 10:55 AM Recurrence With Concurrent or Sequential Radiation Dose Escalation to the Surgical Cavity in High-Risk Early Breast Cancer As reported in the Journal of Clinical Oncology by Vicini et al, the phase III NRG/RTOG 1005 trial has shown noninferior risk for ipsilateral breast recurrence (IBR) with concurrent vs sequential radiation dose escalation to the surgical cavity in conservative treatment of high-risk early breast... Patients With IBD May Be at Risk for VTE After Colorectal Cancer Surgery Patients with inflammatory bowel disease (IBD) may be at a greater risk for postoperative venous thromboembolism (VTE) at least 30 days after surgery for colorectal cancer, according to the results of a large, retrospective study presented at the 2026 Digestive Disease Week Conference. Tuesday, May 19, 2026 12:15 PM Ficerafusp Alfa Plus Pembrolizumab: 2-Year Outcomes in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma As reported in the Journal of Clinical Oncology by Hanna et al, the 2-year follow-up of the expansion cohort in a phase I/Ib trial indicates persistent benefit of first-line ficerafusp alfa plus pembrolizumab in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell... Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer In a phase I/II trial (RMC-6236-001) reported in The New England Journal of Medicine, Wolpin et al identified the safety profile of daraxonrasib and showed activity of the agent in patients with previously treated advanced RAS-mutated pancreatic ductal adenocarcinoma (PDAC). Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief... Tuesday, May 19, 2026 10:00 AM Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response (pCR) in almost half of patients with stage I to III mismatch repair–deficient (dMMR) colon... Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen (PSA) screening is low in younger men—but rises sharply with age. The study, which aimed to estimate the impact of age on overdiagnosis of prostate cancer 15 years after screening stops, analyzed... Wednesday, April 29, 2026 10:35 AM FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. Monday, May 18, 2026 10:00 AM Advanced Prostate Cancer: Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide In a post hoc analysis of the phase III ARCHES and PROSPER trials reported in the Journal of Clinical Oncology, Armstrong et al found that radiographic progression (rPD) often occurred without prostate-specific antigen (PSA) rise in patients with advanced prostate cancer receiving the androgen... Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5... Monday, May 18, 2026 11:33 AM FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA... Friday, May 15, 2026 2:22 PM Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study Sigmoidoscopy screening led to reduced incidence of colorectal cancer, though more for men vs women, and a reduced rate of colorectal cancer–related mortality in men, according to findings from the randomized, controlled NORCCAP trial published in the Annals of Internal Medicine. Friday, May 15, 2026 12:00 PM Early Ovarian Cancer: Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival In a retrospective cohort study reported as a research letter in JAMA Oncology, Matsuo et al found an increasing use of minimally invasive surgery (MIS), an association of MIS with intraoperative capsule rupture, and an association of capsule rupture with poorer survival in patients with early... |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC
Kidney injury molecule-1 (KIM-1) is overexpressed in renal cell carcinoma (RCC), and consistent shedding of this cell-surface protein into the circulation makes it a promising blood-based biomarker for this disease. Herein, we outline potential roles of circulating KIM-1 in diagnosis, prognostication and therapeutic monitoring of RCC, as well as research priorities for clinical translation of this biomarker. Wed, 20 May 2026 00:00:00 -0700 Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons The management of gastro-oesophageal adenocarcinoma (GEA) is undergoing substantial changes owing to evolving treatment paradigms and new therapeutic strategies on the background of a shifting global epidemiology. This Review discusses the state-of-the-art perioperative management of resectable GEA, with an emphasis on how biological heterogeneity influences geographical practice patterns, and outlines future directions for research including precision medicine approaches, biomarker-guided immunotherapy and tailored surgical approaches. Fri, 15 May 2026 00:00:00 -0700 Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer Thu, 14 May 2026 00:00:00 -0700 Clinical implementation of multi-cancer early detection tests: can we find a path forward? On 3 February 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was enacted, enabling Medicare coverage for multi-cancer early detection (MCED) tests. This legislation coincides with new results from key clinical trials and has important implications for payers and policymakers, given the lack of FDA approval of any MCED test or evidence that population screening with such tests reduces cancer-related or all-cause mortality. Thu, 14 May 2026 00:00:00 -0700 Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer The historical development of plasma Epstein–Barr virus DNA for informing clinical decisions for patients with nasopharyngeal carcinoma has culminated in the EP-STAR trial. The circulating tumour DNA clearance patterns observed during neoadjuvant chemotherapy could be used to guide adjuvant therapy, improve outcomes and possibly reflect differences in tumour biology. Herein we discuss why this study constitutes a full-circle moment and provides valuable insights for advancing circulating tumour DNA-based applications in precision oncology. Wed, 06 May 2026 00:00:00 -0700 The transformative role of SBRT in the management of spinal metastases Spinal metastases are associated with debilitating pain and neurological deterioration as well as a poor prognosis and have historically been managed with a palliative intent. Now, following the emergence of stereotactic body radiotherapy (SBRT), more effective pain control as well as control of the metastatic lesions is becoming feasible. In this Review, the authors describe the development and role of SBRT in the management of spinal metastases. Tue, 05 May 2026 00:00:00 -0700 Synergistic integration of regional and systemic therapies in uveal melanoma Treatments for metastatic uveal melanoma utilize various liver-directed strategies, yet optimal integration with systemic therapy is unclear. Here we examine recent evidence indicating that combining percutaneous hepatic perfusion with immune-checkpoint inhibitors might improve patient outcomes, compare it with data from other trials and highlight key questions around patient selection, sequencing and mechanisms that will shape future strategies. Wed, 29 Apr 2026 00:00:00 -0700 Emerging trends in the global burden of colorectal cancer The incidence of colorectal cancer (CRC) has historically been the highest among Western, high-income countries but is now increasing globally beyond these regions. Early-onset CRC (diagnosed before the age of 50 years) has been the main driver of this rise, and risk factors including dietary and lifestyle aspects, the gut microbiota and environmental contaminants have been proposed to underlie these epidemiological trends. The authors of this Review discuss the available evidence on these risk factors, highlighting how the under-representation of non-Western populations in these studies is limiting progress. Tue, 28 Apr 2026 00:00:00 -0700 |
|
|
| |||
|
Predictive model based on folate receptor-positive circulating tumor cells in neoadjuvant immunochemotherapy for esophageal cancer
Vol 17, No 2 (April 30, 2026): Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study Vol 17, No 2 (April 30, 2026): The prevalence of gastric intestinal metaplasia in the Saudi population: a single-tertiary center retrospective study Vol 17, No 2 (April 30, 2026): Prognostic impact of low absolute skeletal muscle mass 6 months after gastrectomy for gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Diagnostic value of mini-probe endoscopic ultrasound in preoperative tumor nodal (TN) staging of gastric cancer and analysis of factors influencing T-staging accuracy Vol 17, No 2 (April 30, 2026): Transcatheter arterial embolization with N-butyl cyanoacrylate versus gelatin sponge particles for gastric cancer-related upper gastrointestinal bleeding: a comparison of efficacy and safety Vol 17, No 2 (April 30, 2026): Postoperative frailty among elderly patients undergoing radical surgery for gastrointestinal tumors and its relationship with prognosis Vol 17, No 2 (April 30, 2026): Molecular characteristics and metastatic mechanism of patients diagnosed with Krukenberg tumor from gastric cancer Vol 17, No 2 (April 30, 2026): Retrospective study on clinical outcomes and safety evaluation of da Vinci robot-assisted laparoscopy and endoscopic cooperative for small gastric stromal tumors resection: preliminary single-center experience Vol 17, No 2 (April 30, 2026): The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis Vol 17, No 2 (April 30, 2026): Comparison of the efficacy and safety of single-incision versus multi-port laparoscopic D2 lymphadenectomy for locally advanced gastric cancer: a systematic review and meta-analysis Vol 17, No 2 (April 30, 2026): Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer Vol 17, No 2 (April 30, 2026): Identification of immunogenic cell death-related prognostic genes in gastric cancer Vol 17, No 2 (April 30, 2026): Opportunistic CT screening for osteosarcopenia predicts reduced overall survival in patients with gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Patterns of recurrence and outcomes of poor responders to neoadjuvant long-course chemoradiotherapy for rectal cancer Vol 17, No 2 (April 30, 2026): Identification of an autophagy-related prognostic signature and validation of WDR45 in colorectal cancer Vol 17, No 2 (April 30, 2026): KRAS mutation subtypes refine prognostic stratification in colorectal cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of manganese metabolism-related genes prognostic model in colorectal cancer and its immunological characteristics Vol 17, No 2 (April 30, 2026): Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II–III colorectal cancer Vol 17, No 2 (April 30, 2026): Assessment of colorectal cancer recurrence risk following solid organ transplantation Vol 17, No 2 (April 30, 2026): CCL5 promotes colon cancer progression via PI3K/AKT signaling and is negatively regulated by STAT1 Vol 17, No 2 (April 30, 2026): Molecular subtyping and prognostic model construction based on endosome-related genes in colorectal cancer Vol 17, No 2 (April 30, 2026): No survival benefit from adjuvant chemotherapy in high-risk stage II small intestinal adenocarcinoma after surgery: a population-based long-term survival analysis Vol 17, No 2 (April 30, 2026): Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience Vol 17, No 2 (April 30, 2026): Single-cell transcriptome analysis identifies neutrophil-related prognostic signatures in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): TRNP1 regulates tumorigenesis and enhances immunotherapy response via c-Kit/STAT3 signaling in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Perioperative clinicopathologic model for predicting 12-month early recurrence after curative hepatectomy in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Association of serum lactate dehydrogenase levels with the severity of microvascular invasion in hepatocellular carcinoma: a retrospective cross-sectional study Vol 17, No 2 (April 30, 2026): An exploratory nomogram model with 18F-FDG PET/CT metabolic parameters for predicting high-risk status of microvascular invasion in hepatocellular carcinoma patients prior to liver transplantation Vol 17, No 2 (April 30, 2026): Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs Vol 17, No 2 (April 30, 2026): Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing Vol 17, No 2 (April 30, 2026): PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of a model for predicting short-term complications after hepatectomy in patients with primary liver cancer Vol 17, No 2 (April 30, 2026): Temporal change in liver function after stereotactic body radiation therapy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): A novel deep learning and radiomics approach based on DCE-MRI for predicting the P53 mutation status in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Peripheral regulatory T cells trajectory predicts progression-free survival in hepatocellular carcinoma patients during on-demand transarterial chemoembolization using joint model: a prospective study Vol 17, No 2 (April 30, 2026): PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study Vol 17, No 2 (April 30, 2026): Indeterminate nodule-like arterial phase hyperenhancement in the liver on CT: differentiation of hepatocellular carcinomas from vascular pseudolesions using a CT radiomics approach Vol 17, No 2 (April 30, 2026): Association between primary tumor resection and survival in metastatic intrahepatic cholangiocarcinoma: a retrospective cohort study based on the SEER database Vol 17, No 2 (April 30, 2026): Multi-scale deep learning models based on MRI for predicting pathological differentiation and evaluating its association with recurrence-free survival in hepatocellular carcinoma: an explainable machine learning study Vol 17, No 2 (April 30, 2026): Daily increment of residual liver regeneration (DIRER) predicts tumor recurrence and mortality after radical hepatectomy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Silencing OTUB1 induces pyroptosis to inhibit the growth of liver cancer HepG2 cells via the NLRP3/caspase/GSDM signaling pathway Vol 17, No 2 (April 30, 2026): Targeting AKR1C1 overcomes lenvatinib resistance in hepatocellular carcinoma through the STAT3-ABC transporters pathway Vol 17, No 2 (April 30, 2026): Multi-institutional care is associated with improved survival in biliary tract cancer Vol 17, No 2 (April 30, 2026): Development and validation of machine learning models integrating spectral computed tomography-derived three-dimensional quantitative parameters for predicting histopathological grade in pancreatic ductal adenocarcinoma Vol 17, No 2 (April 30, 2026): A biomarker-integrated nomogram for predicting postoperative pancreatic fistula in low- to intermediate-risk patients after pancreaticoduodenectomy Vol 17, No 2 (April 30, 2026): Impact of preoperative body weight on short-term and long-term prognosis after pancreatic resection for pancreatic ductal adenocarcinoma: a multicenter study Vol 17, No 2 (April 30, 2026): A TRPM4-associated necrotic cell death signature for prognostic stratification in pancreatic cancer Vol 17, No 2 (April 30, 2026): Single-nucleus RNA sequencing reveals the effects of key regulators on human pancreatic adenocarcinoma and its tumor microenvironment Vol 17, No 2 (April 30, 2026): Neoadjuvant radiotherapy after chemotherapy does not improve surgical or survival outcomes in borderline resectable pancreatic cancer Vol 17, No 2 (April 30, 2026): A systematic review of artificial intelligence and machine learning for gut microbiome-based CRC screening Vol 17, No 2 (April 30, 2026): Multimodal data-driven prediction of postoperative recurrence and survival in hepatocellular carcinoma: a narrative review Vol 17, No 2 (April 30, 2026): Risk factors for exclusive lung metastasis in colorectal cancer: a comprehensive narrative review Vol 17, No 2 (April 30, 2026): Advances in mitophagy research in hepatocellular carcinoma: mechanisms and therapeutic implications Vol 17, No 2 (April 30, 2026): A case report of rectal squamous cell carcinoma following radiation therapy for prostate cancer: a management dilemma Vol 17, No 2 (April 30, 2026): Diagnostic challenges in gastrointestinal stromal tumors: a case report of concurrent gastrointestinal stromal tumor, lymphangioma, and solid pseudopapillary neoplasm of the pancreas Vol 17, No 2 (April 30, 2026): Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report Vol 17, No 2 (April 30, 2026): Gastric lymphoma presenting with predominant pancreatitis and cranial neuropathy: a rare clinical presentation—a case report Vol 17, No 2 (April 30, 2026): A case report of gastroesophageal adenocarcinoma with yolk sac tumor differentiation in a pregnant patient Vol 17, No 2 (April 30, 2026): The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers Vol 17, No 2 (April 30, 2026): Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a critical review Vol 17, No 2 (April 30, 2026): Methodological clarifications on maintenance fluoropyrimidines in advanced esophagogastric adenocarcinoma: a real-world Mexican cohort Vol 17, No 2 (April 30, 2026): Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data Vol 17, No 2 (April 30, 2026): Interpreting the evidence base for fruquintinib in refractory metastatic colorectal cancer Vol 17, No 2 (April 30, 2026): Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151 Vol 17, No 2 (April 30, 2026): Personalised neoadjuvant therapy, based on tumour characteristics and patient choice, is the best way forward in rectal cancer Vol 17, No 2 (April 30, 2026): Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? —a decade of debate! Vol 17, No 2 (April 30, 2026): Emerging mechanisms of kinase inhibitor escape and clinical implications of ponatinib in advanced gastrointestinal stromal tumor Vol 17, No 2 (April 30, 2026): When precision medicine meets human behavior: limits of artificial intelligence in predicting imatinib adherence Vol 17, No 2 (April 30, 2026): Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Muscling in on body surface area to reduce oxaliplatin-induced peripheral neuropathy in colon cancer Vol 17, No 2 (April 30, 2026): Clearing the bar: adding anti-VEGF therapy to chemoimmunotherapy for biliary tract cancer Vol 17, No 2 (April 30, 2026): Maximizing the “toolbox” for patients with initially unresectable colorectal liver metastases: have liver mets “met” their match? Vol 17, No 2 (April 30, 2026): The 12-node rule in irradiated rectal cancer: time for reappraisal? Vol 17, No 2 (April 30, 2026): Beyond drug toxicity: the hidden burden of financial toxicity in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Gastrointestinal malignancies in pregnancy: practical considerations Vol 17, No 2 (April 30, 2026): Intrahepatic cholangiocarcinoma: the equity gap in one of the most lethal cancers Vol 17, No 2 (April 30, 2026): Adjuvant chemotherapy in elderly colon cancer patients: when less may be more Vol 17, No 2 (April 30, 2026): Sarcopenia in esophageal cancer: from passive prognostic marker to active treatment target Vol 17, No 2 (April 30, 2026): Return on investment, return of risk: private equity in gastrointestinal cancer care Vol 17, No 2 (April 30, 2026): Tumor necrosis as a key refinement of risk stratification in gastric gastrointestinal stromal tumors Vol 17, No 2 (April 30, 2026): Survival outcomes in early gastric cancer: evidence from SEER-based population studies Vol 17, No 2 (April 30, 2026): Spontaneous rupture of hepatocellular carcinoma: mechanobiology, rescue, and oncologic control Vol 17, No 2 (April 30, 2026): From waste to wealth: malignant ascites-derived organoids as a compass for precision therapy in advanced gastrointestinal cancers Vol 17, No 2 (April 30, 2026): Erratum: Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings Vol 17, No 2 (April 30, 2026): Retraction: Interfering HMGB3 release from cancer-associated fibroblasts by miR-200b represses chemoresistance and epithelial-mesenchymal transition of gastric cancer cells Vol 17, No 2 (April 30, 2026): |
ASO Visual Abstract: Assessing Recent Trends in Lumpectomy and Concomitant Oncoplastic Procedures: A National Insurance Database Analysis
Thu, 28 May 2026 00:00:00 -0700 ASO Author Reflections: Precision in Reoperative Pancreas-Preserving Surgery for Pancreatic Adenocarcinoma Thu, 28 May 2026 00:00:00 -0700 ASO Visual Abstract: Superiority of [⁶⁸Ga]Ga-FAPI-04 Over [1⁸F]-FDG PET/CT and Conventional Imaging in Detecting Peritoneal Carcinomatosis Thu, 28 May 2026 00:00:00 -0700 Laparoscopic Minimally Invasive Approach for Left Paracaval Retroperitoneal Schwannoma Thu, 28 May 2026 00:00:00 -0700 ASO Author Reflections: From Intuition to Strategy: Traction and Countertraction in Robotic Liver Surgery Thu, 28 May 2026 00:00:00 -0700 ASO Author Reflections: From Four Spatial-Input Strategies to a Full Exhaustive Paradigm—Refining Deep Learning Radiomics for Challenging Renal Masses Thu, 28 May 2026 00:00:00 -0700 ASO Author Reflections: Neuronal Signature Enrichment Distinguishes a Type of Gastric Cancer with Poor Prognosis Thu, 28 May 2026 00:00:00 -0700 ASO Visual Abstract: Closing the Gap: A Longitudinal Review of the Trends of Gender Representation in the Society of Surgical Oncology Membership and Annual Meetings Wed, 27 May 2026 00:00:00 -0700 ASO Visual Abstract: Exploring the Associations and Mechanisms Between Antihypertensive Drugs and Urologic Tumors—Insights from a Mendelian Randomization Study Wed, 27 May 2026 00:00:00 -0700 ASO Author Reflections: When Age Meets Microvascular Invasion—Uncovering an Ultra-High-Risk Phenotype in Hepatocellular Carcinoma Wed, 27 May 2026 00:00:00 -0700 Response to: “Comparable Does not Mean Equivalent: Causal Inference Gaps in Nutritional Prehabilitation for Malnourished Colorectal Cancer Patients” Wed, 27 May 2026 00:00:00 -0700 To Resect or Not to Resect, That is the Question: Neoadjuvant Therapy as the Necessary Gatekeeper for Surgical Treatment in High-Risk Intrahepatic Cholangiocarcinoma Wed, 27 May 2026 00:00:00 -0700 ASO Author Reflections: It’s Time to Take Dyspepsia Seriously Wed, 27 May 2026 00:00:00 -0700 The Emerging Role of Generalizable Vision–Language Models in Ovarian Cancer Diagnosis Wed, 27 May 2026 00:00:00 -0700 Editorial: From Pixels to Pathology: Can Radiomics Replace the Needle in Pancreatic Neuroendocrine Tumors? Wed, 27 May 2026 00:00:00 -0700 Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video) Wed, 27 May 2026 00:00:00 -0700 The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic Analysis Wed, 27 May 2026 00:00:00 -0700 Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study Wed, 27 May 2026 00:00:00 -0700 ASO Visual Abstract: Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis After Neoadjuvant Therapy for Patients with Clinically Node-Negative Hormone Receptor-Positive, HER2-Negative Breast Cancer Tue, 26 May 2026 00:00:00 -0700 Comparable Does Not Mean Equivalent: Causal Inference Gaps in Nutritional Prehabilitation for Malnourished Colorectal Cancer Patients Tue, 26 May 2026 00:00:00 -0700 Multiplication of Alpha-Fetoprotein and Protein Induced by Vitamin K Absence-II is Associated with Prognosis After Pulmonary Metastasectomy in Hepatocellular Carcinoma Tue, 26 May 2026 00:00:00 -0700 The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with Microsatellitosis Tue, 26 May 2026 00:00:00 -0700 ASO Visual Abstract: The Added Value of Plastic Surgery in the Multidisciplinary Management of Sarcoma Resection: A Multivariable Analysis of Predictors and Postoperative Outcomes Mon, 25 May 2026 00:00:00 -0700 ASO Author Reflections: Refining CT Heterogeneity Scoring to Improve Clear Cell Renal Cell Carcinoma Diagnosis in Small Renal Masses Mon, 25 May 2026 00:00:00 -0700 ASO Author Reflections: Peritoneal Disease Control after Complete Cytoreductive Surgery in Patients with Colorectal Cancer and Extraperitoneal Metastases Mon, 25 May 2026 00:00:00 -0700 ASO Visual Abstract: Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age Mon, 25 May 2026 00:00:00 -0700 Psychosocial Interventions for Patients Undergoing Gastrointestinal Cancer Surgery: A Systematic Review Mon, 25 May 2026 00:00:00 -0700 Improving Clear Cell Renal Cell Carcinoma Diagnosis: Modified CT Algorithms with Simplified Heterogeneity Scoring Mon, 25 May 2026 00:00:00 -0700 Association Between Quantitative Blood Flow Measurement Using SPY-QP Software and Prevention of Anastomotic Leakage in Esophageal Cancer Surgery Mon, 25 May 2026 00:00:00 -0700 Optimizing Deep Learning for Renal Mass Characterization in Challenging Cases: A Comparative Study of Spatial-Input Strategies and a Validated ROI-Only DLR Nomogram Mon, 25 May 2026 00:00:00 -0700 Lymph Node Dissection in Biliary Tract Cancers: Time for a Rethink? Sat, 23 May 2026 00:00:00 -0700 How to Deal with Median Arcuate Ligament during Pancreaticoduodenectomy? Management Strategies and Impact on Perioperative Outcomes Sat, 23 May 2026 00:00:00 -0700 Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response Sat, 23 May 2026 00:00:00 -0700 ASO Author Reflections: Beyond Systemic Metabolism: The Prognostic Value of the Significant Intra-pancreatic Fat Deposition in High-grade Pancreatic Neuroendocrine Neoplasms Fri, 22 May 2026 00:00:00 -0700 Increased Mortality with Surgeon Adoption of Robotic Pancreaticoduodenectomy: A National EHR Study of Outcomes Fri, 22 May 2026 00:00:00 -0700 The Added Value of Plastic Surgery in the Multidisciplinary Management of Sarcoma Resection: A Multivariable Analysis of Predictors and Postoperative Outcomes Fri, 22 May 2026 00:00:00 -0700 ASO Author Reflections: From Representation to Equity in the Society of Surgical Oncology Thu, 21 May 2026 00:00:00 -0700 ASO Visual Abstract: Locoregional Control from Complete Peritoneal Cytoreduction in Patients with Extraperitoneal Colorectal Cancer Metastases: An Entropy Balanced Analysis Thu, 21 May 2026 00:00:00 -0700 ASO Author Reflections: Tailoring Hepatic Artery and Celiac Axis Dissection to Tumor Biology in Robotic Pancreaticoduodenectomy: Applying the Inoue Principles Thu, 21 May 2026 00:00:00 -0700 Thoughts on the Changing Trends of Perioperative Depressive Symptoms: Differences Between Breast/Prostate Cancer and Other Solid Tumors Thu, 21 May 2026 00:00:00 -0700 A Stepwise Approach to Laparoscopic Mesohepatectomy: From Complexity to Standardization with Video Demonstration Thu, 21 May 2026 00:00:00 -0700 ASO Special Article: Proceedings of the Inaugural Joint US–India Cancer Dialogue: Accelerating Collaboration to Advance Cancer Prevention, Early Detection, Treatment, and Care Thu, 21 May 2026 00:00:00 -0700 The Ideal Number of Examined Lymph Node Stations for Accurate Nodal Staging and Prognosis in Pathological T1–2 Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Cohort Study Thu, 21 May 2026 00:00:00 -0700 ASO Author Reflections: A Practical Prediction Model for Clinically Relevant Post-Hepatectomy Liver Failure After Major Liver Resection for HCC Wed, 20 May 2026 00:00:00 -0700 Robotic Hepatic Artery Infusion Pump Placement after Recurrent Colorectal Liver Metastasis following Open Left Hemihepatectomy Wed, 20 May 2026 00:00:00 -0700 Leaving the Axilla Untouched: Toward Surgical De-escalation in Early Luminal A Breast Cancer Wed, 20 May 2026 00:00:00 -0700 Impact of Muscle Mass Loss on Survival During Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-center Retrospective Study in China (TIMES Study) Wed, 20 May 2026 00:00:00 -0700 Clinical Outcomes of First-Line Immune Checkpoint Inhibitor–Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer Wed, 20 May 2026 00:00:00 -0700 Correction: Assessing Recent Trends in Lumpectomy and Concomitant Oncoplastic Procedures: A National Insurance Database Analysis Tue, 19 May 2026 00:00:00 -0700 ASO Author Reflections: Revealing Hidden Liver Anatomy Through ICG-Visualized Venous Congestion Tue, 19 May 2026 00:00:00 -0700 |
||
|
| |||
|
What You May Have Missed in 2025
Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Cardiology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Endocrinology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Gastroenterology/Hepatology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Infectious Diseases: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Nephrology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Oncology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Pulmonology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Rheumatology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID Annals of Internal Medicine, Volume 179, Issue 5, Page 621-628, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Short Versus Longer Antibiotic Duration for Community-Acquired Pneumonia Annals of Internal Medicine, Volume 179, Issue 5, Page 629-636, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Firearm Acquisition and New Exposure to Household Firearms After the Initial Pandemic Purchasing Surge: Results From the 2024 National Firearms Survey Annals of Internal Medicine, Volume 179, Issue 5, Page 637-644, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Multisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Risk Annals of Internal Medicine, Volume 179, Issue 5, Page 645-655, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain Annals of Internal Medicine, Volume 179, Issue 5, Page 656-665, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Functional Status of Adults at Risk of Medicaid Disenrollment Under National Work Requirements Annals of Internal Medicine, Volume 179, Issue 5, Page 666-672, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 673-684, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 685-695, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Prevention of Recurrent Nephrolithiasis in Adults and Children Annals of Internal Medicine, Volume 179, Issue 5, Page 696-707, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Determining the Conclusiveness of Systematic Review Evidence Annals of Internal Medicine, Volume 179, Issue 5, Page 708-720, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 COVID-19 Vaccines for 2025–2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 728-733, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 734-739, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Fostering Support and Inclusion for Physicians, Postgraduate Trainees, and Medical Students With Disabilities: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 721-724, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Improving the Health of and Access to Health Care for People With Disabilities: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 725-727, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Dementia: Clinical Challenges Annals of Internal Medicine, Volume 179, Issue 5, Page 740-741, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Incentivizing Deprescribing for Health Care Quality Not Quantity Annals of Internal Medicine, Volume 179, Issue 5, Page 742-743, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 The Current Threat to the U.S. Preventive Services Task Force and Why It Matters Annals of Internal Medicine, Volume 179, Issue 5, Page 744-745, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more than 50%. Analysts say the decision to initiate a last-stage trial reflects a lack of confidence in an accelerated FDA nod.
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant (ORSERDU®) in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026 Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC) U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer |
Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for at least six months after stopping treatment.
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication After being hit by safety issues and subpar results in another trial, BioMarin’s Phase 3 test of Voxzogo for a rare skeletal disorder called hypochondroplasia showed efficacy “solidly above” what the drug has shown for achondroplasia, which causes dwarfism.
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop BioMarin’s investigational therapy failed to elicit clinical improvements in patients with ENPP1 deficiency, while also missing key secondary endpoints of rickets severity and growth.
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval.
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3 The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also noting last year’s Phase 3 failure in chronic obstructive pulmonary disease.
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 Nielsen BioSciences Announces Positive Phase 3 Trial Results of CANDIN for the Treatment and Clearance of Common Warts Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 2026 Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome |
Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for at least six months after stopping treatment.
France’s biotech ecosystem: science, capital and scale In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
Kura’s encouraging cancer drug data could unlock $2B market opportunity Nearly 80% of patients saw tumor shrinkage after being treated with Kura Oncology’s darlifarnib plus Bristol Myers Squibb’s Krazati, findings Mizuho analysts say could open up a $2 billion opportunity for the biotech.
Germany can produce biotech winners. Europe must back them better. Strong science and early support are not enough on their own. Europe needs more capital depth, cross-border investor backing and a lighter policy framework to keep companies scaling at home, according to two venture capitalists.
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos Kissei Pharmaceutical is reversing a recommendation related to Amgen-shared Tavneos that it made just a few days ago, now saying the rare disease drug can be given to new patients.
BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication After being hit by safety issues and subpar results in another trial, BioMarin’s Phase 3 test of Voxzogo for a rare skeletal disorder called hypochondroplasia showed efficacy “solidly above” what the drug has shown for achondroplasia, which causes dwarfism.
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Draig Therapeutics Presents New Phase 1 Data Demonstrating Safety, Tolerability, Pulsatile PK and Target Engagement by DT-101, a Novel AMPA Receptor Potentiator, at ASCP Annual Meeting Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant (ORSERDU®) in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO |
|
|
| |||
|
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer
On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:02 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:02 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:02 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:02 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:02 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:02 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:02 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:02 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:02 -0700
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:02 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:02 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:02 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:02 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:02 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:02 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:02 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:02 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:02 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:02 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:02 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:02 -0800
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:02 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:02 -0800
|
Microglial mitochondria transfer to astrocytes via GPNMB-enriched extracellular vesicles alleviates cognitive deficits in tauopathy mice.
Nat Neurosci. 2026 May 26. doi: 10.1038/s41593-026-02317-w. Liang C, Zhou Y, Zhuang K, Wang S, Zhong L, Can D, Lei A, Li H, Zhang J, Leng L Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Res. 2026 Jun;46(6):3243-3255. doi: 10.21873/anticanres.18194. Hulscher N, Victory K, Thorp JA, Pinsky D, Diaz-Villalobos A, Gillooly P, Coulson F, Annazone M, Radesi C, Brooks J, McCULLOUGH PA, Risch H Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. N Engl J Med. 2026 May 28;394(20):2002-2014. doi: 10.1056/NEJMoa2517729. Shitara K, Elimova E, Liu T, Tabernero J, Lee KW, Schenker M, Tebbutt NC, Ajani J, Salimin N, Ku G, Gwang Kim J, Ales Diaz I, Zhang J, Pietrantonio F, Bai LY, Le Sourd S, Zhao J, Hierro C, Kiberu A, Van Herpe F, Bao Y, Zhang H, Yang L, Li V, Gartner EM, Chen Y, Grim J, Rha SY, Shen L; HERIZON-GEA-01 Investigators Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. N Engl J Med. 2026 May 28. doi: 10.1056/NEJMoa2515131. Hou J, Lim SG, Buti M, Yuen MF, Gane E, Lampertico P, Terrault N, Nguyen H, Yim HJ, Xie Q, Lin J, Qiu Y, Jeng WJ, Heo J, Peng CY, Chen CH, Chuang WL, Xie Y, Hlebowicz M, Idriz N, Mehta R, Agarwal K, Gomes da Silva MM, Franca A, Cernat R, Leerapun A, Coffin CS, Gadano A, Andreone P, Fujiyama S, Sevastianos V, Suzuki Y, Ratziu V, Riachi G, Stocker H, Lim TH, Asselah T, Tanaka Y, Holmes J, Liang X, Cremer J, Lukić T, Plein H, Quinn G, Tao Y, Paff M, Theodore D, Elston R; B-Well Study Group Updated trends in the global prevalence and burden of mental disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2026 May 23;407(10543):2040-2064. doi: 10.1016/S0140-6736(26)00519-2. GBD 2023 Mental Disorder Collaborators Universal transcriptomic hallmarks of mammalian ageing and mortality. Nature. 2026 May 27. doi: 10.1038/s41586-026-10542-3. Tyshkovskiy A, Kholdina D, Davitadze M, Molière A, Moldakozhayev A, Tongu Y, Kasahara T, Glubokov D, Eames A, Kats LM, Vladimirova A, Ying K, Liu H, Zhang B, Khasanova U, Moqri M, Van Raamsdonk JM, Harrison DE, Strong R, Abe T, Dmitriev SE, Gladyshev VN Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure. N Engl J Med. 2026 May 28;394(20):1991-2001. doi: 10.1056/NEJMoa2513525. Zimmermann WH, Ensminger S, Kutschka I, Paitazoglou C, Seidler T, Brandenburg S, Anker SD, Bader N, Bergau L, Bremmer F, Diogo PG, Eitel I, Fujita B, Gerecke B, Hasenfuß G, Hellenkamp K, Hermann-Lingen C, Jebran AF, Jurczyk D, Knaus R, Legler T, Lotz J, Placzek M, Pühler T, Riggert J, Sadlonova M, Saraei R, Ströbel P, Tiburcy M, Ullrich C, Voigt JU, Walker F, Wollnik B, Yigit G, Friede T; BioVAT-HF Investigators Farnesylation-driven KRAS phase separation promotes colon tumor growth. Cell. 2026 May 27:S0092-8674(26)00519-2. doi: 10.1016/j.cell.2026.05.002. Wang X, Zhang Y, Lu M, Gong Y, Guan T, Hou G, Wei Y, Wang M, Liu H, Huang L, Zheng S, Lin Q, Zhang W, Xiang Z, Ma J, Li L, Meng H, Tong X, Ji H, Huang J, Hu Y Spatiotemporal transcriptome atlas of human embryos after gastrulation. Nature. 2026 May 27. doi: 10.1038/s41586-026-10545-0. Pan J, Li Y, Lin Z, Lan Q, Zhang Y, Chen H, Sui S, Zhai M, Zhang G, Cheng Y, Tang Y, Wang Q, Xu Y, Li G, Xu C, Yan H, Mao Y, Wang X, Li H, Zhu Y, Chen Q, Guan Y, Meng N, Wang C, Lu H, Li X, Zheng T, Yao X, Yang T, Chen X, Qin Q, Jiang B, Ren Y, Liu X, Zhang Y, Yu M, Wang L, Wei Y, Luo M, Nancuo J, Ma F, Wang Z, Ou Z, Lei Y, Jin X, Sheng J, Xu C, Wu Y, Xu C, Zhao L, Yang H, Gao Y, Ding G, Xu X, Huang H In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. N Engl J Med. 2026 May 25. doi: 10.1056/NEJMoa2601283. Vafai SB, Täubel J, Ashdown T, Patel RS, Diamondali S, Cegla J, Soran H, Bashir B, Abitbol A, Gaudet D, Lauzière A, Brunham LR, Newby DE, Nicholls SJ, Scott RS, Kerr J, Tardif JC, Lunken C, Humphries SE, Karsten V, Tyler PD, Zhang X, Huniti N, Flight PA, Jensen CL, Falzone R, Biedenkapp JC, Lister T, Stolz LE, Khera AV, Kathiresan S Evaluation and Treatment of Baseball Pitchers: There's More to Assess than the Arm. Int J Sports Phys Ther. 2025 Jan 1;20(1):113-126. doi: 10.26603/001c.127461. eCollection 2025. Gauthier ML, Unverzagt CA, Davies GJ Lonely minds, inflamed guts: metabolic and circulating protein pathways linking social isolation and loneliness to inflammatory bowel disease. Transl Psychiatry. 2026 May 22. doi: 10.1038/s41398-026-04116-0. Zhao J, Ye J, Zhang M, Yu G, Ji H, Zhou S, Jiang F, Xue E, Li K, Yu Z, Yang H, Wu H, Li X Uncovering spatially resolved functional genomics with CRISPR screen sequencing. Cell. 2026 May 26:S0092-8674(26)00516-7. doi: 10.1016/j.cell.2026.04.049. Zhang H, Zhang Z, Wang P, Xu T, Chen X, Zhao Y, Lin S, Cai W, Ren P, Luo C, Zhang P, Wang Y, Hou S, Zhao Y, Zeng H, Liu Z, Wang C, Gao Z, Feng Y, Pan D, Zeng Z Human haematopoietic stem cells remember inflammatory stress. Nature. 2026 May 27. doi: 10.1038/s41586-026-10522-7. Zeng AGX, Nagree MS, Jakobsen NA, Shah S, Varesi A, Kang JRW, Murison A, Cheong JG, Turkalj S, Zhang X, Radtke FA, Abera TA, Lim INX, Jin L, Araújo J, Aguilar-Navarro AG, Parris D, McLeod J, Kim H, Lee HS, Zhang L, Boulanger M, Bader E, Gbeha E, Parkhurst CN, Wagenblast E, Flores-Figueroa E, Wang B, Schwartz GW, Shultz LD, Nam AS, Grimes HL, Josefowicz SZ, Awadalla P, Vyas P, Dick JE, Xie SZ The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression. Mol Psychiatry. 2026 Mar 5. doi: 10.1038/s41380-026-03510-w. Nakajima W, Hatano M, Ohtani Y, Tani H, Yatomi T, Tsuchimoto S, Fujimoto Y, Eiro T, Ichijo S, Nakano K, Arisawa T, Takada Y, Kimura K, Abe H, Sano A, Nomoto-Takahashi K, Yonezawa K, Tomiyama S, Nagai N, Kusudo K, Honda S, Moriyama S, Nakajima S, Yamada T, Iwabuchi Y, Jinzaki M, Yoshimura K, Syed SA, Tsugawa S, Uchida H, Takahashi T TPPP/p25 amyloid seeding activity as a specific biomarker for multiple system atrophy. Cell. 2026 May 26:S0092-8674(26)00517-9. doi: 10.1016/j.cell.2026.04.050. Zeng S, Zhang S, Zhang S, Fan Y, Xia W, Chen F, Huang C, Lv S, Lu J, Sun Y, Liu K, Li Y, Zhang Y, Wang J, Liu C, Li D β-Arrestin condensates regulate G-protein-coupled receptor function. Nature. 2026 May 27. doi: 10.1038/s41586-026-10539-y. Anderson PJ, Xiao P, Zhong YN, Kaakati AN, Alfonso-DeSouza J, Patino A, Ahn A, Jassal C, Zhang T, Zhang C, Yu K, Qi L, Ding W, Liu S, Pani B, Krishnan A, Chen O, Strawn J, Snyder JC, Sun JP, Rajagopal S [OCULO-ORBITAL TUMOURS AT THE NATIONAL UNIVERSITY HOSPITAL CENTRE OF BANGUI (CNHUB), CENTRAL AFRICAN REPUBLIC, IN 2022]. Med Trop Sante Int. 2023 Jul 3;3(3):mtsi.v3i3.2023.396. doi: 10.48327/mtsi.v3i3.2023.396. eCollection 2023 Sep 30. Elien Gagnan Yan Zaou Tou RR, Mbaïkoua JM, Kosh Komba Palet JE, Guirou N Leishmaniasis. N Engl J Med. 2026 May 28;394(20):2026-2039. doi: 10.1056/NEJMra2403309. Aronson NE, Musa AM, Satoskar AR αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. Nature. 2026 May 27. doi: 10.1038/s41586-026-10584-7. Uboveja A, Yang B, Buj R, Amalric A, Wang H, Tangudu NK, Cole AR, Disharoon JA, Fang RS, Levasseur E, Naruse M, Huang Z, Megill E, Kantner DS, Chatoff A, Ahmad H, Marcinkiewicz MM, Graff S, De Pieri E, Huacachino AA, Vendetti FP, Danielson J, Dahl ES, Pennise JL, Elishaev E, Jaccard A, Borho L, Post MD, Cooper K, Modugno F, Hempel N, Stallaert W, Bakkenist CJ, Sidoli S, Wellen KE, Bitler BG, Long DT, Snyder NW, Aird KM |
||